GB2443304A - Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). - Google Patents
Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). Download PDFInfo
- Publication number
- GB2443304A GB2443304A GB0720409A GB0720409A GB2443304A GB 2443304 A GB2443304 A GB 2443304A GB 0720409 A GB0720409 A GB 0720409A GB 0720409 A GB0720409 A GB 0720409A GB 2443304 A GB2443304 A GB 2443304A
- Authority
- GB
- United Kingdom
- Prior art keywords
- aids
- extract
- treatment
- pharmaceutical formulation
- immune deficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 title claims abstract description 15
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 25
- 235000001619 Agave salmiana Nutrition 0.000 claims abstract description 18
- 241000196324 Embryophyta Species 0.000 claims abstract description 15
- 244000103849 Tradescantia spathacea Species 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 10
- 238000002347 injection Methods 0.000 claims abstract description 10
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960004194 lidocaine Drugs 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 6
- 235000011837 pasties Nutrition 0.000 claims abstract description 4
- 239000008213 purified water Substances 0.000 claims abstract description 4
- 238000007918 intramuscular administration Methods 0.000 claims abstract 2
- 229960005486 vaccine Drugs 0.000 claims abstract 2
- 240000006617 Agave salmiana Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000233835 Tradescantia Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000005406 washing Methods 0.000 abstract description 2
- 240000004246 Agave americana Species 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000233833 Commelinaceae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical formulation for the treatment of Acquired Immune Deficiency Syndrome (AIDS) comprising an extract of Purple Maguey (Tradescantia spathacea). Said formulation preferably comprises a 1ml intramuscular vaccine containing: 250mg or Tradescantia spathacea extract; 30mg USP Propilenglicol; 1mg lidocaine hydrochlorate; and 1ml injection water. Also claimed is a method for producing a pharmaceutical formulation for treatment of (AIDS) comprising: washing a whole plant with purified water; cutting said plant into pieces, liquidisation; filtration; and boiling until a black yellowish pasty substance is obtained.
Description
1 2443304
PHARMACEUTICAL FORMULATION FOR TREATMENT OF ACQUIRED IMMUNE
DEFICIENCY SYNDROME (AIDS). OBTAINING PROCEDURE.
This invention is involved with Pharmaceutical branch in general and in particular with a substance obtained out of purple maguey (T,adescantia Spatlacea) that allows getting pharmaceutical formulations useful to treat Acquired Immune Deficiency Syndrome (AIDS), as well as its obtaining process.
It is widely known that this pandemic is still growing and what is a serious problem: there are some countries which exhibited sustainable low rates of AIDS infection or even rates of infection tending to decrease, and these countries have experienced an increase in recent times.
According to a recent report issued by AIDS UNO/WHO about the situation of AIDS pandemic in 2006, it is estimated that more than 40 millions of people are living with AIDS in the world; 4.3 millions of new infections occurred just in 2006. 65% of them (2.8 millions) were located in Sub-Saharan Africa what comes to be added to the dramatic increases in countries of Eastern Europe and Central Asia where there are some clues indicating an increase in infection rates in more that 50% just from 2004.
Just in 2008 2.9 millions of people died due to several diseases related to AIDS.
Up to this moment AIDS has no cure and about 15 medicines are being used to treat the infection. Treatment includes the combination of several antiretroviral medicines that avoid immunological depression and stop virus multiplication. Antiretroviral therapy is complex and expensive since it includes the administration of al least three medicines (triple therapy) several times a day and high doses that produces non desired effects interacting with other medicines that should be taken with or without meals. But what is worst is the fact that this therapy does not guarantee the total cure and the elimination of the disease.
Beside antiretroviral therapy mentioned above, there is a study about therapeutic properties of some plants that could be really used for getting a final cure for this terrible disease, and it is precisely in this technological field in which this invention is framed in.
On the other hand, curative properties of maguey in general are well known and in particular its applications to gastrointestinal and skin diseases also, what has generated a great interest in the study of other therapeutic applications of these plants lately.
Patent MXJLO40000I7 is known in technique state and today it is in application stage under the title of "MAGUEY (AGAVE SALMIANA) PLANT EXTRACT FOR CURING HUMAN VIRUS DISEASES" with the priority number MX2004JL00017 20040707. The applicant's name is BELTRAN JOSE GARIBAY. Use of maguey extract to cure viral diseases like AIDS is restored in this study. A method to obtain the extract is included in this patent which consists in pressing the plant (previously washed) with metal rolls to extract its juice which is kept and ready to be used. However, it is known all maguey species are commonly toxic, so its application in human beings is not possible in a direct way without generating a toxic reaction pretty aggressive.
Tradescantia Spathacea plant or purple maguey belongs to the Commelinaceae family composed by 44 genres and about 600 species, is a herb with thick silky juicy dark purple (on the opposite side) leaves, its height is about 20 and 25 cm and its width about 3.5 cm. Its stem is about 20 cm height, white three petals (5 to 8 mm) flowers and rough seeds (3 mm length and 1.5 mm width). This plant has gone through several trials since early 90s and it has been possible to state that this plant contains some substances known as flavonics and cumancs Which have anti-inflammatory properties.
Recent researches focus on the plant have revealed that it also eliminates formation of tumors, and have been successfully tested on mama tissue, prostate, skin, colon and tumor affections related to leukemia.
Already mentioned uses related to Tradoscantia Spathacea are listed in the technique state as well as its use in the elaboration of cosmetics and pharmaceutical products focused on dermatologic appliances as it is stated in patent W09909945 entitled "USE OF THE RHOEO DISCOLOR PLANT EXTRACTS IN COSMETICS AND PHARMACEUTICS, IN PARTICULAR IN DERMATOLOGY" whose applicant is CENTRE NAT RECH SCIENT from France.
Besides the properties and applications mentioned above, the present researcher has now discovered that Traclescantia Spathacea is particularly useful in treatments related to AIDS, and it is not previously known or reported this application in the technique state.
A procedure is disclosed below to obtain a substance out of purple maguey (Tradescantia Spathacea).
Pharmaceutical formulations are disclosed below obtained from purple maguey extract (Tradescantia Spathacea), used to eliminate acquired immune deficiency syndrome AIDS.
A method of treatment is disclosed below based on such pharmaceutical formulations for the treatment of AIDS patients.
Getting purple maguey extract (Tradescantia Spathacea) begins with the use of the whole plant which goes through a washing process using purified water to eliminate impurities, then the plant is cut into pieces of 3 or 4 inches to be introduce in a professional liquid izer to get the plant juice. After this, extract is filtered to eliminate fibers and final juice is boiled in a stainless recipient to eliminate existing water in order to obtain a pasty black yellowish substance.
The present researcher has discovered this final product obtained out of purple maguey (Tradescantia Spathacea) is useful to fight against infections caused by human immune deficiency virus. Tests done to animals in lab allowed to check animals infected with AIDS which received a treatment with purple maguey extract injections and several doses of the extract after a period of time were totally healthy, what was supported by lab tests and the application of BlO-Card HIVI/2/0 (Fast Test for Qualitative Detection of Antibodies HIV) and even by ELISA methods.
However, extract of purple maguey has a pasty and dense consistency which makes no possible its application directly on a living being. Also it is considered to be toxic and irritant. So, it has been mixed with hydrochlorate of lidocaine because it is necessary to reduce toxicity and to avoid non desired reactions in patients. Then, to improve moisturizing properties it should be mixed with propelinglicol and to be applied in injections should be mixed with water injection. In this way every mixture becomes a different pharmaceutical formulation from the same extract.
An example of the action spectrum of the present invention is given.
To get extract from purple maguey (Tradescantia Spathacea) I select the whole plant, wash it during 10 minutes using purified water till impurities are totally removed. Then the plant is cut into pieces of 3 inches and it is put into an industrial mixer to triturate it in order to get an extract with fibers which are eliminated once this extract if filtered.
After filtering process, obtained extract is kept in a stainless recipient and is boiled to evaporate as much water as possible. The final result is a black yellowish paste.
A pharmaceutical formula (injection lmL) that can be obtained from purple maguey extract (Tradescantia Spathacea) is given with an illustrative and no limitative character. This formula has the following composition: Tradescantia Spathacea extract 250 mg.
USP Propilenglicol. 3 mg.
hydrochloride of lidocaine I mg.
Injection water c.s.p. 1 ml.
Other pharmaceutical formulations can be gotten from mentioned extract, so it Is not limited to the injection formula given above. New formulations can be powders, capsule, tablets, coated pills, creams, gels, solutions, injections, ointment and syrups.
The invention is concerned with the active product, namely Tradescantia Spathacea extract, itself, with pharmaceutical formulations comprising such active product, includkig but not limited to formulations comprising the active product together with Propilenglicol (propyleneglycol) and hydrochloride of lidocaine, with methods of manufacture of the active product and of pharmaceutical formulations comprising such product, and with use of Tradescanlia Spathacea extract and medicaments made therefrom for the treatment or alleviation of HIV/AIDS.
Claims (5)
- CLAIMS: 1. Pharmaceutical formulation for treatment of Acquired ImmuneDeficiency Syndrome (AIDS). Obtaining procedure characterized by getting it out of purple maguey extract (Tradescantia Spa fhacea).
- 2. Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). Obtaining procedure according to claim I characterized by its composition since active ingredient is purple maguey extract (T,adescantia Spathacea), USP Propilenglicol, Hydrochlorate of lidocaine, and injection water.
- 3. Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). Obtaining procedure according to claims 1 and 2 characterized by I mL intramuscular vaccine containing proportions of 250 mg of Tradescantia Spathacea extract, 30mg USP Propilenglicol, I mg Hydrochiorate of lidocaine and 1 mL of injection water.
- 4. Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). Obtaining procedure characterized by getting the extract out of a selected whole plant which is carefully washed using purified water. then plant is cut into pieces, liquidized, filtered and boiled till getting a black yellowish pasty substance.
- 5. Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). Obtaining procedure according to claims 1, 2, and 3, is characterized by the application of a quantity therapeutically appropriate of purple maguey (Tradescantia Spathacea) extract to an AIDS virus Infected patient
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0720409A GB2443304A (en) | 2007-10-18 | 2007-10-18 | Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0720409A GB2443304A (en) | 2007-10-18 | 2007-10-18 | Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0720409D0 GB0720409D0 (en) | 2007-11-28 |
| GB2443304A true GB2443304A (en) | 2008-04-30 |
Family
ID=38814391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0720409A Withdrawn GB2443304A (en) | 2007-10-18 | 2007-10-18 | Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2443304A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999013892A1 (en) * | 1997-09-12 | 1999-03-25 | Laboratorios Pisa, S.A. De C.V. | Antimastitic pharmaceutical composition and preparation process |
-
2007
- 2007-10-18 GB GB0720409A patent/GB2443304A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999013892A1 (en) * | 1997-09-12 | 1999-03-25 | Laboratorios Pisa, S.A. De C.V. | Antimastitic pharmaceutical composition and preparation process |
Non-Patent Citations (2)
| Title |
|---|
| Emanations Vol.3, 2001. Cobarrubias et al. "Comparative Analysis of the Chemistry and Bioactivity of Medicinal Cacti and Succulent Plants in the Dominican Republic." Abstract available online from http://labs.plantbio.cornell.edu/cbl/Pubs/Emanations3.html [Accessed 18th Feb 2008]. * |
| Songklanakarin J.Sci.Technol. Vol.29 Suppl.1 2007. Sriwanthana et al. "In vitro effects of Thai medicinal plants on human lymphocyte activity." pp.17-28. Available from: http://www.sjst.psu.ac.th/journal/29_Suppl_1_Thaiherb_II_pdf/03busarawan_17-28.pdf [Accessed 15 Feb 2008]. * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0720409D0 (en) | 2007-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mishra et al. | Phcog rev.: Plant review Andrographis paniculata (Kalmegh): A review | |
| EP3076984B1 (en) | Herbal combinations for treatment of a skin condition | |
| Sabale et al. | Curcuma longa Linn. A phytochemical and phytopharmacological review | |
| Elumalai et al. | A review on Ceiba pentandra and its medicinal features | |
| US8535737B2 (en) | Composition with extracts from olive leaf, yarrow and rosemary for treating human diseases and conditions | |
| US20170000836A1 (en) | Prognostic and Diagnostic Methods and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer | |
| US10561678B2 (en) | Composition for treating neuropathy, process and method of treatment thereof | |
| US20170000837A1 (en) | Prognostic and Diagnostic Kits and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer | |
| Mehta et al. | Recent patent technologies of boswellic acids: A short review. | |
| US20080102139A1 (en) | Pharmaceutical Formulation for Treatment of Acquired Immune Deficiency Syndrome (AIDS). | |
| Pradhan et al. | A comprehensive review on phytochemistry, molecular pharmacology, clinical and translational outfit of Ocimum sanctum L. | |
| WO2017019651A1 (en) | Herbal combinations for treating psoriasis | |
| GB2443304A (en) | Pharmaceutical formulation for treatment of Acquired Immune Deficiency Syndrome (AIDS). | |
| Farasati Far et al. | The potential role of Hypericum perforatum in wound healing: A literature review on the phytochemicals, pharmacological approaches, and mechanistic perspectives | |
| JP5980292B2 (en) | β-secretase inhibitor and acetylcholinesterase inhibitor | |
| KR100515419B1 (en) | Whitening cosmetics composition comprising natural herb extracts | |
| Riaz et al. | Treasures hunt in old mines: Terminalia chebula-Based traditional herbal medicinal products | |
| Sardari et al. | Bioactivity Assays of Eryngium thyrsoideum; Focusing on Cytotoxic Effects, Antioxidant Activity, and Antimalarial Properties | |
| KR20120090123A (en) | Composition of film forming solution for alleviation of menstrual cramp | |
| MX2007012902A (en) | A pharmaceutical formulation and its use for the treatment of acquired immune deficiency syndrome (aids) and other aids related diseasesand a process for its preparation | |
| Gayakwad et al. | DEVELOPMENT AND IN-VIVO STUDY OF POLYHERBAL ORAL DISPERSIBLE FILM FOR THE MANAGEMENT OF EMESIS | |
| MP et al. | Protective Effect Of Polyherbal Formulation Kabasura Kudineer Against COVID-19. | |
| RU2353348C1 (en) | Broad-spectrum ointment for allergic dermopathies | |
| JPH03106818A (en) | External drug composition for skin | |
| Abd El-gawad | Natural Products as Enzyme Inhibitors for Production of Biologically Active Agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |